REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2021.10.22 | 07:00 | Permanent Information Releases / General Company News

puce Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease - HTML (w)

2021.10.22 | 07:00 | Permanent Information Releases / General Company News

puce Dupixent® (dupilumab) – premier médicament biologique ayant permis d’obtenir une réduction significative des démangeaisons et lésions cutanées causées par le prurigo nodulaire, une maladie inflammatoire de type 2, dans le cadre d’un essai d - HTML (w)

2021.10.20 | 23:30 | Permanent Information Releases / General Company News

puce FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma - HTML (w)

2021.10.20 | 23:30 | Permanent Information Releases / General Company News

puce La FDA approuve l’extension des indications de Dupixent® (dupilumab) au traitement de l’asthme modéré à sévère de l’enfant de 6 à 11 ans - HTML (w)

2021.10.13 | 09:00 | Permanent Information Releases / General Company News

puce New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 - HTML (w)

2021.10.13 | 09:00 | Permanent Information Releases / General Company News

puce Présentation à l’ECTRIMS 2021 de nouvelles données à long terme qui confortent le profil de tolérance et d’efficacité du tolébrutinib à pénétration cérébrale - HTML (w)

2021.10.01 | 20:28 | Share History / Voting Rights and Number of Shares

puce Sanofi: Information concerning the total number of voting rights and shares - August 2021 - HTML (w)

2021.10.01 | 20:28 | Share History / Voting Rights and Number of Shares

puce Sanofi: Informations relatives au nombre de droits de vote et d'actions - Aout 2021 - HTML (w)

2021.09.30 | 14:30 | Permanent Information Releases / General Company News

puce New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis - HTML (w)

2021.09.30 | 14:30 | Permanent Information Releases / General Company News

puce Présentation à l’EADV de nouvelles données de dernière minute sur le profil clinique émergent de l’amlitélimab (anciennement KY1005), chez l’adulte atteint de dermatite atopique modérée à sévère inadéquatement contrôlée - HTML (w)

2021.09.28 | 08:00 | Permanent Information Releases / Sales and Revenues

puce Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate - HTML (w)

2021.09.28 | 08:00 | Permanent Information Releases / Sales and Revenues

puce Sanofi annonce des résultats intermédiaires positifs de phase I/II pour son premier candidat-vaccin à base d’ARNm - HTML (w)

2021.09.24 | 07:30 | Permanent Information Releases / Notification of availability

puce Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes - HTML (w)

2021.09.24 | 07:30 | Permanent Information Releases / Notification of availability

puce Sanofi : Mise en ligne du document « Q3 2021 Memorandum for modelling purposes » - HTML (w)

2021.09.21 | 07:00 | Permanent Information Releases / General Company News

puce New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 3158